A potential treatment of COVID-19 with TGF-β blockade.
作者信息
Chen WanJun
机构信息
Mucosal Immunology Section, NIDCR, National Institutes of Health, Bethesda, MD 202892, USA.
出版信息
Int J Biol Sci. 2020 Apr 21;16(11):1954-1955. doi: 10.7150/ijbs.46891. eCollection 2020.
Abstract
摘要
相似文献
1
A potential treatment of COVID-19 with TGF-β blockade.一种通过阻断转化生长因子-β来治疗新型冠状病毒肺炎的潜在方法。
Int J Biol Sci. 2020 Apr 21;16(11):1954-1955. doi: 10.7150/ijbs.46891. eCollection 2020.
2
Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak.多西环素，一种在皮肤科广泛使用的抗生素，在新冠疫情中可能对白细胞介素-6具有抗炎作用。
Dermatol Ther. 2020 Jul;33(4):e13437. doi: 10.1111/dth.13437. Epub 2020 May 15.
3
COVID-19: the vasculature unleashed.COVID-19：血管失控。
Nat Rev Immunol. 2020 Jul;20(7):389-391. doi: 10.1038/s41577-020-0343-0.
4
COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.新型冠状病毒肺炎、肺肥大细胞、细胞因子风暴以及木犀草素的有益作用
Biofactors. 2020 May;46(3):306-308. doi: 10.1002/biof.1633. Epub 2020 Apr 27.
5
COVID-19 as a cause of immune thrombocytopenia.新型冠状病毒肺炎作为免疫性血小板减少症的一个病因
Med Mal Infect. 2020 Aug;50(5):459-460. doi: 10.1016/j.medmal.2020.05.003. Epub 2020 May 20.
6
How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.新冠病毒是如何致人死亡的？不确定性正阻碍医生选择治疗方法的能力。
Nature. 2020 Apr;580(7803):311-312. doi: 10.1038/d41586-020-01056-7.
7
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
8
Audio Interview: Acute Lung Injury in Covid-19.音频访谈：新冠病毒肺炎相关急性肺损伤
N Engl J Med. 2020 Jul 9;383(2):e32. doi: 10.1056/NEJMe2024719.
9
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.继发性噬血细胞性淋巴组织细胞增生症、HScore与2019冠状病毒病
Int J Hematol. 2020 Jul;112(1):125-126. doi: 10.1007/s12185-020-02895-w. Epub 2020 May 30.
10
[Not Available].[无可用内容]。
Rev Med Suisse. 2020 May 27;16(695):1126.
引用本文的文献
1
Lyophilized MSC-EVs attenuates COVID-19 pathogenesis by regulating the JAK/STAT pathway.冻干的间充质干细胞外泌体通过调节JAK/STAT信号通路减轻COVID-19的发病机制。
Stem Cell Res Ther. 2025 May 15;16(1):244. doi: 10.1186/s13287-025-04284-8.
2
Haematological Manifestations of SARS-CoV-2: Insights into Erythropoiesis, Hepcidin Regulation, and Cytokine Storm.新型冠状病毒肺炎的血液学表现：对红细胞生成、铁调素调节及细胞因子风暴的见解
Int J Mol Sci. 2025 Jan 21;26(3):874. doi: 10.3390/ijms26030874.
3
State of the Globe: A Glimmer of Hope - Biomarkers for Diagnosing COVID-19 Pulmonary Fibrosis.全球状况：一线希望——用于诊断新冠肺纤维化的生物标志物
J Glob Infect Dis. 2024 Jun 26;16(2):43-44. doi: 10.4103/jgid.jgid_119_24. eCollection 2024 Apr-Jun.
4
Role of TGF-β and p38 MAPK in TSG-6 Expression in Adipose Tissue-Derived Stem Cells In Vitro and In Vivo.TGF-β 和 p38 MAPK 在脂肪组织来源干细胞体外和体内 TSG-6 表达中的作用。
Int J Mol Sci. 2023 Dec 29;25(1):477. doi: 10.3390/ijms25010477.
5
TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis.TGF-β 可使巨噬细胞中的糖酵解与炎症解偶联，并控制脓毒症期间的存活。
Sci Signal. 2023 Aug 8;16(797):eade0385. doi: 10.1126/scisignal.ade0385.
6
Association between SUMF1 polymorphisms and COVID-19 severity.SUMF1 多态性与 COVID-19 严重程度的关联。
BMC Genom Data. 2023 Jun 21;24(1):34. doi: 10.1186/s12863-023-01133-6.
7
Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study.两种抗纤维化治疗方案对新冠后综合征肺纤维化的疗效比较：一项随机前瞻性研究
Med Clin (Engl Ed). 2023 Jun 23;160(12):525-530. doi: 10.1016/j.medcle.2022.12.019. Epub 2023 Jun 16.
8
Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years.评价 COVID-19 患者中肿瘤生长因子-β与Ⅰ型干扰素通路的相互作用：重点关注 1 至 90 岁年龄组。
BMC Infect Dis. 2023 Apr 18;23(1):248. doi: 10.1186/s12879-023-08225-9.
9
Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study.比较两种抗纤维化治疗方案对新冠病毒感染后综合征肺纤维化的疗效：一项随机、前瞻性研究。
Med Clin (Barc). 2023 Jun 23;160(12):525-530. doi: 10.1016/j.medcli.2022.12.021. Epub 2023 Mar 3.
10
Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.调节性T细胞（Tregs）与新冠病毒病（COVID-19）：揭示其机制及治疗潜力，特别关注新冠后综合征
Vaccines (Basel). 2023 Mar 19;11(3):699. doi: 10.3390/vaccines11030699.
Zotero 插件